Pompano Beach, Fla., Nov. 25, 2014 (GLOBE NEWSWIRE) -- DS Healthcare Group, Inc. (NASDAQ: DSKX), a leading developer of personal care products, today announced that the Brazilian Health Surveillance Agency, ANVISA, has approved the Company's Spectral.LASHeyelash extender product for marketing in Brazil.
"Based on the highly successful clinical studies, Brazil's ANVISA has approved our Spectral.LASH for both safety and efficacy. We will immediately begin to market and sell Spectral.LASH through our distribution channels in Brazil's sizeable beauty market and expect Spectral.LASH to be in our top three products sold in Brazil," stated DS Healthcare President and CEO Daniel Khesin. "While consumers have limited options, our highly effective products will help them address real issues. This one of a kind solution is just one example of how we intend to expand our product line and create increased revenues and opportunities throughout Brazil. We continue to have a pipeline of products awaiting approvals and anticipate continued sales growth across all sales regions on an on-going basis as we expand our global footprint. DS Healthcare currently has distribution agreements with three personal care and pharmacy retail chains and are expecting additional agreements within the coming months, as well as sales through its Brazilian e-commerce site (www.dslaboratories.com/br). According to market research firm Euromonitor, the Brazilian beauty industry generated $42 billion in sales in 2012.
In an independent clinical study, patients using Spectral.LASH, a cutting-edge treatment from DS Laboratories, resulted in 100% of users experiencing 25% thicker eyelashes within four weeks. Spectral.LASH deploys a breakthrough peptide complex, and scientists believe that peptides, composed of structural amino acids, work by stimulating the expression of keratin genes and by improving overall eyelid health.
About DS Healthcare Group
DS Healthcare Group Inc. leads in the development of biotechnology for topical therapies. It markets through online and specialty retailers, distributors, cosmetics wholesalers, and salons. Its research has led to a highly innovative portfolio of personal care products and additional innovations in pharmaceutical projects. For more information on DS Health Group's flagship brand, visit www.dslaboratories.com
Except for statements of historical fact, the matters discussed in this press release are forward-looking and made pursuant to the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies, and are generally preceded by words such as "future," "plan" or "planned," "expects," or "projected." These forward-looking statements reflect numerous assumptions and involve a variety of risks and uncertainties, many of which are beyond the company's control that may cause actual results to differ materially from stated expectations. These risk factors include, among others, limited operating history, difficulty in developing and marketing products, intense competition, and additional risks factors as discussed in reports filed by the company with the Securities and Exchange Commission, which are available at http://www.sec.gov.
CONTACT: Laurel Moody Corporate Profile 1.646.810.0608
Source:DS Healthcare Group,Inc.